Infections, immunity and atherosclerosis: Pathogenic mechanisms and unsolved questions

International Journal of Cardiology

Volumn 166, Issue 3, 2013, Pages 572-583

  Pedicino, Daniela ^a   Giglio, Ada Francesca ^a   Galiffa, Vincenzo Alessandro ^a   Cialdella, Pio ^a   Trotta, Francesco ^a   Graziani, Francesca ^a   Liuzzo, Giovanna ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Atherosclerosis; Autoimmunity; Infection; Inflammasome; Toll like receptors

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; CHAPERONIN 60; ERITORAN; GELATINASE B; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PATTERN RECOGNITION RECEPTOR; PHOSPHOLIPASE D; PRAVASTATIN; PROSTACYCLIN; THROMBOMODULIN;

ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL METABOLISM; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL METABOLISM; CORRELATION ANALYSIS; CROSS REACTION; CYTOKINE PRODUCTION; ELECTRON MICROSCOPY; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; MORPHOLOGY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SEQUENCE HOMOLOGY; VIRUS REPLICATION; ANIMAL; AUTOIMMUNITY; COMMUNICABLE DISEASE; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNITY; COMMUNICABLE DISEASES; HUMANS; IMMUNITY;

EID: 84893512951     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.098     Document Type: Review

References (200)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
2. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from patho-physiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
3. Hansson GK Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
4. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30: 1282-92.
5. Liuzzo G, Biasucci LM, Gallimore JM, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
6. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
7. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91.
8. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
9. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2: 644-7.
10. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and non atherosclerotic patients. Am J Pathol 1989; 134: 1151-7.
11. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-8.
12. Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2: 291-3.
13. Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol 1994; 42: 33-7.
14. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573-7.
15. Bruggeman CA Does cytomegalovirus play a role in atherosclerosis? Herpes 2000; 7: 51-4.
16. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-9.
17. Muhlestein J, Horne B, Carlquist J, et al. C-reactive protein and citomegalovirus antibody levels predict mortality in patients with angiographically defined coronary artery disease. J Am Coll Cardiol 1999; 33: 317A.
18. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-7.
19. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study. Circulation 2000; 102: 2335-40.
20. Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis 2000; 182: 1583-7.
21. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-12.
22. Guan XR, Li X, Xin XM, et al. Previous HIV infection took part in the development of atherosclerosis and trigger the occurrence of AMI. Inflammation 2008; 31: 266-72.
23. Liu SC, Tsai CT, Wu CK, et al. Human parvovirus B19 infection in patients with coronary atherosclerosis. Arch Med Res 2009; 40: 612-7.
24. Kuo HK, Fujise K. Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006. J Am Coll Cardiol 2011; 58: 2001-6.
25. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
26. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
27. Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121-8.
28. Blasi F, Cosentini R, Raccanelli R, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997; 112: 309-12.
29. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H. Chlamydia pneumonia infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832-7.
30. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.
31. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2002; 23: 371-5.
32. Westerhout CM, Gnarpe J, Chang WC, et al. No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. Am Heart J 2007; 154: 306-12.
33. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-9.
34. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 559-69.
35. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a metaanalysis. Am Heart J 2007; 154: 830-7.
36. Friedewald VE, Kornman KS, Beck JD, et al. The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol 2009; 104: 59-68.
37. Epstein SE, Zhu J. Lack of association of infectious agents with risk of future myocardial infarction and stroke: definitive evidence disproving the infection/coronary artery disease hypothesis? Circulation 1999; 100: 1366-8.
38. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-8.
39. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004; 25: 25-31.
40. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29: 1350-8.
41. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocar-dial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9: 601-10.
42. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32: 1730-5.
43. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation 2006; 114: 1549-53.
44. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-40.
45. Burnett MS, Gaydos CA, Madico GE, et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis 2001; 183: 226-31.
46. Li L, Messas E, Batista Jr EL, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002; 105: 861-7.
47. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001; 103: 2834-8.
48. Ott SJ, El Mokhtari NE, Musfeldt M. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006; 113: 929-37.
49. Kol A, Sperti G, Shani J, et al. Cytomegalovirus replication is not a cause of instability in unstable angina. Circulation 1995; 91: 1910-3.
50. Ishihara K, Nabuchi A, Ito R, Miyachi K, Kuramitsu HK, Okuda K. Correlation between detection rates of periodontopathic bacterial DNA in coronary stenotic artery plaque and in dental plaque samples. J Clin Microbiol 2004; 42: 1313-5.
51. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.
52. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-8.
53. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724-31.
54. Liu R, Yamamoto M, Moroi M, et al. Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology. Am Heart J 2005; 150: 681-8.
55. Spagnoli LG, Pucci S, Bonanno E, et al. Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction. Am J Pathol 2007; 170: 33-42.
56. Liuzzo G, Ciervo A, Niccoli G, et al. Chlamydia pneumoniae in coronary atherosclerotic plaques and coronary instability. Int J Cardiol 2011; 147: 176-8.
57. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
58. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 35: 404-7.
59. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60.
60. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.
61. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332: 22-7.
62. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
63. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azith-romycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-13.
64. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
65. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
66. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15: 60-8.
67. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 2001; 52: 3-31.
68. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999; 99: 1555-9.
69. Yusuf SW, Mishra RM. Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischaemic heart disease. Acta Cardiol 2002; 57: 317-22.
70. Majka J, Róg T, Konturek PC, et al. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Monit 2002; 8: CR675-84.
71. Lu YH, Yen HW, Lin TH, et al. Changes of coronary risk factors after eradication of Helicobacter pylori infection. Kaohsiung J Med Sci 2002; 18: 266-72.
72. Leung WK, Ma PK, Choi PC, et al. Correlation between Helicobacter pylori infection, gastric inflammation and serum homocysteine concentration. Helicobacter 2001; 6: 146-50.
73. Schweeger I, Fitscha P, Sinzinger H. Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. Thromb Res 2000; 97: 411-20.
74. Guetta E, Guetta V, Shibutani T, Epstein SE. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein: possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ Res 1997; 81: 8-16.
75. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20.
76. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100:e20-8.
77. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect Immun 1999; 67: 2909-15.
78. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-73.
79. Speir E, Yu ZX, Ferrans VJ, Huang ES, Epstein SE. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998; 83: 210-6.
80. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177(3): 725-9.
81. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factoralpha and matrix metalloproteinase expression. Circulation 1998; 28(98): 300-7.
82. Johnston SC, Zhang H, Messina LM, Lawton MT, Dean D. Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum. Arterioscler Thromb Vasc Biol 2005; 25: 2648-53.
83. Arno G, Kaski JC, Smith DA, Akiyu JP, Hughes SE, Baboonian C. Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart 2005; 91: 521-5.
84. Benagiano M, Munari F, Ciervo A, et al. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A 2012; 109: 1222-7.
85. Visser MR, Tracy PB, Vercellotti GM, Goodman JL, White JG, Jacob HS. Enhanced thrombin generation and platelet binding on herpes simplex virus-infected en-dothelium. Proc Natl Acad Sci U S A 1988; 85: 8227-30.
86. Key NS, Vercellotti GM, Winkelmann JC, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A 1990; 87: 7095-9.
87. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990; 61: 657-62.
88. van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992; 68: 364-70.
89. Yoshida T, Koide N, Mori I, Ito H, Yokochi T. Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells. FEMS Microbiol Lett 2006; 260: 17-22.
90. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999; 100: 2135-9.
91. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-8.
92. Liuzzo G, Vallejo AN, Kopecky SL, et al. Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 2001; 103: 1509-14.
93. Liuzzo G, Biasucci LM, Trotta G, et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 2007; 50: 1450-8.
94. Giubilato S, Liuzzo G, Brugaletta S, et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 2011; 32(10): 1214-26.
95. Zal B, Kaski JC, Arno G, et al. Heat shock protein reactive CD4+CD28-T cells in patients with acute coronary syndromes. Circulation 2004; 109: 1230-5.
96. Dimitriu IE, Araguás ET, Baboonian C, Kaski JC. CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 2009; 81: 11-9.
97. Liuzzo G, Angiolillo DJ, Buffon A, et al. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 2001; 103: 2236-41.
98. Angiolillo DJ, Liuzzo G, Pelliccioni S, et al. Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina. J Am Coll Cardiol 2003; 41: 546-50.
99. Olivares-Zavaleta N, Carmody A, Messer R, Whitmire WM, Caldwell HD. Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways. J Immunol 2011; 186: 7120-6.
100. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-α and Toll-Like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116: 2043-52.
101. Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999; 100: 1569-75.
102. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74.
103. Münz C, Lünemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9: 246-58.
104. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 1547-59.
105. Morimoto RI Cells in stress: transcriptional activation of heat shock genes. Science 1993; 259: 1409-10.
106. Gupta S, Knowlton AA. Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 2002; 106: 2727-33.
107. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 1993; 142: 1927-37.
108. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-9.
109. Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000; 102: 14-20.
110. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegård J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 2000; 36: 303-7.
111. Grundtman C, Kreutmayer SB, Almanzar G, Wick MC, Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 960-8.
112. Herz I, Rosso R, Roth A, Keren G, George J. Serum levels of anti heat shock protein 70 antibodies in patients with stable and unstable angina pectoris. Acute Card Care 2006; 8: 46-50.
113. Zhang X, Xu Z, Zhou L, et al. Plasma levels of Hsp70 and anti-Hsp70 antibody predict risk of acute coronary syndrome. Cell Stress Chaperones 2010; 15: 675-86.
114. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.
115. George J, Shoenfeld Y, Afek A, et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 1999; 19: 505-10.
116. Zhu J, Katz RJ, Quyyumi AA, et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation 2004; 109: 36-41.
117. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunization. Atherosclerosis 2003; 167: 177-85.
118. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-9.
119. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
120. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-7.
121. Huittinen T, Leinonen M, Tenkanen L, et al. Synergistic effect of persistent Chlamydia pneumoniae infection, autoimmunity, and inflammation on coronary risk. Circulation 2003; 107: 2566-70.
122. Biasucci LM, Liuzzo G, Ciervo A, et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003; 107: 3015-7.
123. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-94.
124. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-9.
125. Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002; 106: 430-4.
126. Netea MG, Kullberg BJ, Galama JM, Stalenhoef AF, Dinarello CA, van der Meer JW. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 2002; 32: 1188-95.
127. Selzman CH, Netea MG, Zimmerman MA, et al. Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. J Thorac Cardiovasc Surg 2003; 126: 688-93.
128. Froberg MK, Adams A, Seacotte N, Parker-Thornburg J, Kolattukudy P. Cytomegalovirus infection accelerates inflammation in vascular tissue overexpressing monocyte chemoattractant protein-1. Circ Res 2001; 89: 1224-30.
129. Fabricant CG, Hajjar DP, Minick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells Am. J Pathol 1981; 105: 176-84.
130. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180: 780-90.
131. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-61.
132. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010; 134: 5-24.
133. Vallejo JC Role of toll-like receptors in cardiovascular diseases. Clin Sci (Lond) 2011; 121: 1-10.
134. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
135. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
136. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis: an alternative view on an outdated hypothesis. Pharmacol Rep 2008; 60: 85-92.
137. Shinohara M, Hirata K, Yamashita T, et al. Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol 2007; 27: 2384-91.
138. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-8.
139. Otsui K, Inoue N, Kobayashi S, Shiraki R, Honjo T, Takahashi M. Enhanced expression of TLR4 in smooth muscle cells in human atherosclerotic coronary arteries. Heart Vessels 2007; 22: 416-22.
140. Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine and innate immunity-related inflammatory mechanisms. Innate Immun 2008; 14: 63-87.
141. Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y, Akamura M. Local expression of toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci 2008; 115: 133-40.
142. Wyss CA, Neidhart M, Altwegg L, et al. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010; 31: 1457-69.
143. Yonekawa K, Neidhart M, Altwegg LA, et al. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis 2011; 218: 486-92.
144. Kuwahata S, Fujita S, Orihara K, et al. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 2010; 209: 248-54.
145. Geng HL, Lu HQ, Zhang LZ, et al. Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol 2006; 143: 269-73.
146. Shiraki R, Inoue N, Kobayashi S, et al. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci 2006; 80: 59-66.
147. Mizoguchi E, Orihara K, Hamasaki S, et al. Association between Toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 2007; 18: 31-8.
148. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-61.
149. Ashida K, Miyazaki K, Takayama E, et al. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb 2005; 12: 53-60.
150. Versteeg D, Hoefer IE, Schoneveld AH, et al. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart 2008; 94: 770-6.
151. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009; 120: 2462-9.
152. Cole JE, Navin TJ, Cross AJ, et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A 2011; 108: 2372-7.
153. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
154. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107: 2416-21.
155. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23:e61-4.
156. Hamann L, Gomma A, Schröder NW, et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med (Berl) 2005; 83: 478-85.
157. Yang IA, Holloway JW, Ye S. Southampton Atherosclerosis Study (SAS) Group. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170: 187-90.
158. Morange PE, Tiret L, Saut N, et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12: 1041-9.
159. Hua F, Ha T, Ma J, et al. Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. J Immunol 2007; 178: 7317-24.
160. Sakata S, Lebeche D, Sakata Y, et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 2007; 292:H1204-7.
161. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of Toll-like receptor4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114:I270-4.
162. Arslan F, Smeets MB, O'Neill LA, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121: 80-90.
163. Erridge C. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis 2011; 216: 1-6.
164. Lalla E, Lamster IB, Hofmann MA, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apoliporotein E-null mice. Arterioscler Thromb Vasc Biol 2003; 23: 1405-11.
165. Kuula H, Salo T, Pirilä E, et al. Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun 2009; 77: 850-9.
166. de Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. Br Med J 2010; 340:c2451.
167. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
168. Dinarello CA A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203-17.
169. Guarda G, So A. Regulation of inflammasome activity. Immunology 2010; 130: 329-36.
170. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-86.
171. Shaw PJ, Lamkanfi M, Kanneganti TD. NOD-like receptor (NLR) signaling beyond the inflammasome. Eur J Immunol 2010; 40: 624-7.
172. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
173. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243: 136-51.
174. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev 2011; 243: 152-62.
175. He X, Mekasha S, Mavrogiorgos N, Fitzgerald KA, Lien E, Ingalls RR. Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol 2010; 184: 5743-54.
176. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 314-21.
177. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-88.
178. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 2012; 13: 352-7.
179. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-61.
180. Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: anovel link between cholesterol metabolism and inflammation. PLoS One 2010; 5:e11765.
181. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011; 477: 596-600.
182. Miao EA, Alpuche-Aranda CM, Dors M, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006; 7: 569-75.
183. Miao EA, Mao DP, Yudkovsky N, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A 2010; 107: 3076-80.
184. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011; 243: 206-14.
185. Choubey D. DNA-responsive inflammasomes and their regulators in autoimmunity. Clin Immunol 2012; 142: 223-31.
186. Bloemenkamp DGM, Mali WPTM, Visseren FLJ, van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? Am Heart J 2003; 145: 409-17.
187. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 2009; 119: 3133-41.
188. Gieffers J, Fullgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
189. Jeffrey L, Anderson MD. Infection, antibiotics, and atherothrombosis - end of the road or new beginnings? N Engl J Med 2005; 352: 1706-9.
190. Kato M, Dote K, Sasaki S, et al. Presentations of acute coronary syndrome related to coronary lesion morphologies as assessed by intravascular ultrasound and optical coherence tomography. Int J Cardiol 2013 May 25; 165(3): 506-11.
191. Uemura S, Ishigami K, Soeda T, et al. Thin-cap fibroatheroma and microchannel findings in optical coherence tomography correlate with subsequent progression of coronary atheromatous plaques. Eur Heart J 2012; 33: 78-85.
192. Brugaletta S, Biasucci LM, Pinnelli M, et al. Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart 2006; 92: 249-50.
193. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
194. Nissen SE High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292: 1365-7.
195. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010; 105: 1371-7.
196. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010; 21: 157-63.
197. Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr Pharm Des 2007; 13: 367-85.
198. Murdin AD, Dunn P, Sodoyer R, et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis 2000; 181:S544-51.
199. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-14.
200. Maron R, Sukhova G, Faria AM, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1708-15.